

S11.4 SEROLOGICAL SCREENING FOR SYPHILIS: RESEARCH NEEDS

doi:10.1136/sextrans-2011-050102.47

S A Lukehart. *University of Washington, Washington, Seattle, USA*

Background and problem The recent development and implementation of serological screening for syphilis using recombinant protein-based immunoassays has resulted in much confusion about the interpretation of positive results, particularly in low prevalence settings. Early experience suggests that a high proportion of positive tests are not confirmed by either non-treponemal or other treponemal tests. Many questions remain about the accuracy and relevance of these results.

Research needs We will discuss research questions related to the performance, utility, and effectiveness of these tests.

Performance of the existing tests Sensitivity, specificity, and positive predictive value in high- and low-prevalence populations. What gold standard should be used for evaluation of these tests?

Can performance of the existing tests be improved by simple modifications?

Reactivity in persons with past treated syphilis—how can this be determined?

Effectiveness of using the current tests for screening Does screening with the EIA tests result in the need for more additional, unnecessary testing? Does the delay in receiving prompt complete serological results result in delayed treatment and increased transmission of syphilis? How much unnecessary treatment results from the use of these tests for screening? What is the impact of EIA screening on public health time and dollars spent on contact tracing? What is the real cost of EIA screening, including the need for additional testing, possibility of additional transmission, and required public health follow-up?

Biological basis for the unconfirmed reactivity in the existing tests - Which *Treponema pallidum* antigens are recognised by patient sera that are reactive only in the EIA tests?

Do such antisera have cross-reactivity with antigens of other treponemal species found in humans?

Next generation recombinant protein-based antibody tests Are there *T pallidum*-specific antigens? How can we identify them? Are there antigens for which antibody disappears or declines significantly following treatment?

Conclusions The increasingly widespread use of recombinant protein-based immunoassays has contributed to much confusion in serological testing for syphilis. Research efforts to understand the source of the problems with these first-generation tests are needed to provide clinicians with appropriate algorithms and tools to accurately and rapidly diagnose untreated syphilis in their patients.

Symposium 12: Current topics on human papillomavirus

S12.1 TRANSMISSION OF HUMAN PAPILLOMAVIRUS INFECTIONS

doi:10.1136/sextrans-2011-050102.48

¹A N Burchell, ³F Coutlée, ⁴P Tellier, ²J Hanley, ^{1,2}E L Franco. ¹Department of Oncology, Faculty of Medicine, McGill University, Montreal, Canada; ²Department of Epidemiology and Biostatistics, Faculty of Medicine, McGill University, Montreal, Canada; ³Département de Microbiologie, Centre Hospitalier de l'Université de Montréal, Montreal, Canada; ⁴Department of Family Medicine, Faculty of Medicine, McGill University, Montreal, Canada

Background There have been few studies of the sexual transmission of human papillomavirus (HPV) between partners. Our objective was to estimate transmission rates among persons with docu-

mented sexual exposure to an infected partner and longitudinal follow-up.

Methods We analysed data from the HITCH Cohort Study, a study of recently-formed couples. Women aged 18–24 attending a university or junior college in Montreal, Canada and their male partners were eligible. Self-collected vaginal swabs and clinician-obtained swabs of epithelial cells from the penis and scrotum were tested for DNA of 36 HPV types. We analysed follow-up data at visit 2 from 179 couples who were discordant for one or more HPV types at enrolment. We defined the index partner as that which was infected with a type(s) not found in the other partner, and a transmission event as subsequent detection of that HPV type in the non-index partner. Transmission rates are expressed as the number of transmissions per 100 person-months (PM), with 95% CI estimated using Poisson regression.

Results Transmission was observed in 73 partnerships. There was little difference between the male-to-female (3.5 per 100PM, 95% CI 2.7 to 4.5) and the female-to-male transmission rate (4.0 per 100PM, 95% CI 3.0 to 5.5). These rates are consistent with a per-partnership transmission probability of 0.20 (95% CI 0.16 to 0.24) over 6 months. Transmission rates did not differ with the lifetime number of partners reported by the non-index partner at enrolment or with the circumcision status of the male partner. Rates were highest when the index partner was still positive for that type at follow-up; rates of male-to-female transmission quadrupled and female-to-male transmission tripled (5.2 and 6.2 per 100PM, respectively), compared to when the index partner was negative at follow-up (1.2 and 1.8 per 100PM, respectively, $p < 0.05$).

Conclusions Transmission rates based on follow-up of discordant partners are probably underestimates of the true rate due to clearance in index partner and the depletion of susceptibles. Our results contribute to a small but growing evidence base regarding the natural history of HPV transmission and the probability of transmission. These estimates may be of utility to improve forecasting estimates from mathematical modelling efforts to project the public health impact and cost-effectiveness of HPV vaccination.

S12.2 SCREENING FOR CERVICAL CANCER IN THE ERA OF HPV VACCINATION

doi:10.1136/sextrans-2011-050102.49

E L Franco. *McGill University, Montreal, Canada*

Two efficacious prophylactic vaccines against infections with human papillomavirus (HPV) types 16 and 18 have become available since 2006. Universal pre-exposure HPV vaccination has the potential to reduce the incidence of cervical cancer by up to 75%. Vaccination is also expected to have an impact on the rate of cervical cytological abnormalities and of diagnostic and treatment procedures required to manage women with such precancerous lesions. The traditional paradigm of Pap cytology screening may not be a suitable complementary preventive strategy in the era of HPV vaccination. Once the cohorts of young women who are being vaccinated reach the age of screening the prevalence of Pap smear-detectable abnormalities will decrease substantially, which will ultimately affect the positive predictive value of cytology and decrease its cost-effectiveness. It is now widely accepted that testing cervical exfoliated cells for DNA of high oncogenic risk HPVs is a much more sensitive screening tool than cytology to detect high grade cervical lesions and cervical cancer. Cytologic or HPV-typing triage of HPV-positive women can reveal cases that should undergo colposcopic examination and biopsy and will largely obviate the concerns related to false-positives. With the improved sensitivity to detect existing lesions and the more “upstream” focus on cervical carcinogenesis this strategy could be implemented via longer screening intervals than are currently possible with cytology alone,